Drug intelligence / Profile preview

SYNB1344

Development stage: Discontinued
Lead developer: Synlogic
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

SYNB1344 (SYN-MSUD) is an orally administered, non-pathogenic, engineered strain of *Escherichia coli* Nissle 1917 developed as a "Synthetic Biotic" for the treatment of Maple Syrup Urine Disease (MSUD). MSUD is a rare metabolic disorder characterized by the body's inability to process branched-chain amino acids (BCAAs), specifically leucine, isoleucine, and valine, leading to toxic accumulation. SYNB1344 is genetically modified to express a metabolic pathway that actively consumes these BCAAs within the gastrointestinal tract, thereby reducing their systemic levels and preventing neurological damage. Developed by Synlogic, the program aimed to provide a convenient alternative or adjunct to strict dietary protein restriction. However, development was halted following Synlogic's decision to cease operations and liquidate the company in early 2024.

Beyond the preview

Go deeper on SYNB1344.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYNB1344.

Explore the full profile